Nektar Therapeutics Stock Forecast for 2023 - 2025 - 2030
Updated on 04/24/2024
Nektar Therapeutics Stock Forecast and Price Target
Year-long price target forecasts from two prominent analysts have recently been released for Nektar Therapeutics, with an average price target of $1.00. This potential loss of -29.58 percent from the previous closing price in April, 2024 is calculated on a high forecast of $1.00 and a low estimate of $1.00. Even if you are not interested in NKTR stock, you should still be aware of its competitors.
-29.58% Downside
Nektar Therapeutics Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Nektar Therapeutics's Price has grown, increasing from $0.00 to $0.00 – a growth of 100.00%. The next year looks promising for Nektar Therapeutics, with analysts predicting Fair Value of $1.53 – an increase of 100.00%. Over the next nine years, experts anticipate that Nektar Therapeutics's Fair Value will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| NOVO B Stock Forecast | Novo Nordisk A/S | Outperform |
12
|
kr891.30 | Buy/Sell | kr696.07 | 7.71% |
| BIIB Stock Forecast | Biogen | Outperform |
10
|
$193.18 | Buy/Sell | $299.62 | 51.15% |
| VTRS Stock Forecast | Viatris Inc | Hold |
8
|
$11.36 | Buy/Sell | $11.73 | 5.63% |
| 500124 Stock Forecast | Dr. Reddy's Laboratories | Hold |
18
|
Rp5.95k | Buy/Sell | Rp5.67k | 1.61% |
| 4523 Stock Forecast | Eisai | Outperform |
18
|
¥6.09k | Buy/Sell | ¥9.58k | 37.93% |
Nektar Therapeutics Revenue Forecast for 2023 - 2025 - 2030
Nektar Therapeutics's Revenue has decreased In the last two years, from $152.92M to $92.06M – a 39.80% drop. In the following year, 6 experts forecast Nektar Therapeutics's Revenue will decrease by 12.27%, to $80.76M. Over the next eleven years, experts anticipate that Nektar Therapeutics's Revenue will grow at a rate of 7.32%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 4403 Stock Forecast | NOF | Buy |
18
|
¥2.09k | Buy/Sell | ¥7.63k | 35.76% |
| IRWD Stock Forecast | Ironwood Pharmaceuticals | Buy |
14
|
$8.31 | Buy/Sell | $17.83 | 104.57% |
| ASRT Stock Forecast | Assertio Holdings | Buy |
8
|
$0.91 | Buy/Sell | $3.50 | 229.67% |
.jpg)
Nektar Therapeutics EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Nektar Therapeutics's EBITDA has fallen from $-365.74M to $-227.21M – a 37.88% decrease. According to 1 analysts, Nektar Therapeutics's EBITDA will fall by 76.83% in the next year, reaching $-52.65M. Professionals believe that By 2030, Nektar Therapeutics's EBITDA will fall to $-173.00M – a 23.86% decrease from its current value.
Nektar Therapeutics EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Nektar Therapeutics's EBIT has decreased from $-379.92M to $-240.24M – a 36.77% drop. In the following year, 5 experts forecast that Nektar Therapeutics's EBIT will decrease by 57.93%, to $-101.08M. In 2030, professionals predict that Nektar Therapeutics's EBIT will decrease by 57.46%, to $-102.20M.
Nektar Therapeutics EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Nektar Therapeutics's EPS has grown, increasing from $-2.49 to $0.00 – a growth of 100.00%. The next year looks promising for Nektar Therapeutics, with analysts predicting EPS of $-0.69 – an increase of 100.00%. Over the next nine years, experts anticipate that Nektar Therapeutics's EPS will grow at a rate of 100.00%.
.jpg)